Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis sativa. In recent years, there has been scientific interest in CBDV for seizure disorders, especially epilepsy. Preclinical studies in animal models have shown that CBDV can reduce the frequency and severity of seizures, likely by modulating neuronal excitability and affecting endocannabinoid receptors. These promising findings led to early-phase human clinical trials.

However, clinical evidence remains limited. A few small placebo-controlled trials have investigated CBDV in patients with drug-resistant epilepsy. For instance, a phase IIa randomized, double-blind, placebo-controlled trial (2019) found that CBDV was well tolerated but did not show statistically significant seizure reduction compared to placebo. Subsequent studies are ongoing to assess its efficacy and safety in larger populations and specific epilepsy syndromes.

Currently, CBDV is not approved by regulatory agencies for the treatment of seizures, unlike cannabidiol (CBD), which is the active ingredient in the FDA-approved drug Epidiolex. Thus, while evidence from animal studies is promising, and early-phase human trials suggest safety, robust clinical efficacy data are lacking. Accordingly, the scientific evidence supporting the use of CBDV for seizure control is preliminary, justifying a moderate-low rating of 2 out of 5.

More about Cannabidivarin
More about Seizures

Other ingredients used for Seizures

Other health conditions supported by Cannabidivarin

Products containing Cannabidivarin